LUPIN LTD Company Profile

✉ Email this page to a colleague

LUPIN LTD has one hundred and fifty-eight approved drugs.

There is one US patent protecting LUPIN LTD drugs. There are nineteen tentative approvals on LUPIN LTD drugs.

There are two patent family members on LUPIN LTD drugs in two countries and five hundred and eighty-three supplementary protection certificates in seventeen countries.

International Patents:	2
US Patents:	1
Tradenames:	137
Ingredients:	120
NDAs:	158
Drug Master File Entries:	194
Patent Litigation for LUPIN LTD:	See patent lawsuits for LUPIN LTD
PTAB Cases with LUPIN LTD as petitioner:	See PTAB cases with LUPIN LTD as petitioner

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lupin Ltd	BLISOVI FE 1.5/30	ethinyl estradiol; norethindrone acetate	TABLET;ORAL-28	201585-001	Nov 18, 2015	BX	RX	No	No		⤷ Try a Trial				⤷ Try a Trial
Lupin Ltd	MELOXICAM	meloxicam	CAPSULE;ORAL	209487-001	Jun 1, 2020	AB	RX	No	No		⤷ Try a Trial				⤷ Try a Trial
Lupin Ltd	LEVETIRACETAM	levetiracetam	TABLET, EXTENDED RELEASE;ORAL	091399-001	Sep 12, 2011	AB	RX	No	No		⤷ Try a Trial				⤷ Try a Trial
Lupin Ltd	MOXIFLOXACIN HYDROCHLORIDE	moxifloxacin hydrochloride	SOLUTION/DROPS;OPHTHALMIC	204079-001	May 28, 2015		RX	No	Yes		⤷ Try a Trial				⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Injection	250 mcg/0.5 mL, 1 mL PFS	➤ Subscribe	2012-03-30
➤ Subscribe	for Oral Suspension	500 mg/5 mL	➤ Subscribe	2014-07-22
➤ Subscribe	Delayed-release Tablets	20 mg	➤ Subscribe	2015-06-03

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2007119249	⤷ Try a Trial
Germany	112007000920	⤷ Try a Trial
>Country	>Patent Number	>Estimated Expiration

Subscribe to access the full database, or Try a Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2435025	19C1040	France	⤷ Try a Trial	PRODUCT NAME: COMBINAISON DE GLYCOPYRROLATE (Y COMPRIS TOUS SELS, ESTERS, ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI) ET DE FORMOTEROL (Y COMPRIS TOUS SELS, ESTERS, ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI); NAT. REGISTRATION NO/DATE: EU/1/18/1339 20181220; FIRST REGISTRATION: - EU/1/18/1339 20181220
1559427	300599	Netherlands	⤷ Try a Trial	PRODUCT NAME: MIRABEGRON EN ZOUTEN ERVAN; REGISTRATION NO/DATE: EU/1/12/809/001-014 20130107
1948158	122016000038	Germany	⤷ Try a Trial	PRODUCT NAME: SACUBITRIL/VALSARTAN, ALS SACUBITRIL VALSARTAN NATRIUM SALZKOMPLEX, D.H. TRINATRIUM-(3-((1 S,3R)-1-BIPHENYL-4-YLMETHYL-3-ETHOXYCARBONYL-1-BUTYLCARBAMOYL)PROPIONAT-(S)-3'-METHYL-2'-(PENTANOYL-(2"-(TETRAZOL-5-YLAT)BIPHENYL-4'-YLMETHYL)AMINO)BUTYRAT)-HEMIPENTAHYDRAT.; REGISTRATION NO/DATE: EU/1/15/1058 20151119
1663240	1590057-4	Sweden	⤷ Try a Trial	PRODUCT NAME: A COMBINATION OF RILPIVIRINE, OR A PHARMACEUTICAL LY ACCEPTABLE SALT OF RILPIVIRINE, INCLUDING THE HYDROCHLORIDE SALT OF RILPIVIRINE, AND TENOFOVIR DISOPROXIL, IN PARTICULAR TENOFOVIR DISOPROXIL FUMARATE, AND EMTRICITABINE; REG. NO/DATE: EU/1/11/737 20111128
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.